Literature DB >> 3399837

Immunity against diphtheria and tetanus in the age group 30-70 years.

K Kjeldsen1, O Simonsen, I Heron.   

Abstract

In Denmark, childhood primary vaccination against diphtheria and tetanus has been recommended since 1950. No routine revaccinations or general vaccination of adults have been offered. In most other western countries revaccinations are recommended later in childhood. However, death still occurs from diphtheria and tetanus in countries with such vaccination programs although it is generally accepted that protective immunity can be obtained by vaccination. On this basis the immunity against diphtheria and tetanus was assessed in a random sample of 351 subjects in the age range 30-70 years. Diphtheria antitoxin titres were determined by in vitro neutralization technique using VERO cells. 26% had diphtheria antitoxin titres below protective level (0.01 international antitoxin units/ml serum). The highest number of unprotected against diphtheria was found among 30-39 year old women (68%) and 60-69 year old subjects (36%). Tetanus titres were determined by a combination of ELISA technique and an in vivo neutralization assay. 51% were unprotected against tetanus (less than 0.01 international antitoxin units/ml serum). The highest number of unprotected against tetanus was found among 60-69 year old subjects (68%) and especially among females in this age group (77%). To avoid epidemics of diphtheria in the future the immunity among adults must be raised within the coming years. Thus, revaccination must be recommended and high attendance ensured. One revaccination is sufficient only when complete primary vaccination is documented.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3399837     DOI: 10.3109/00365548809032435

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  17 in total

1.  Immunity to diphtheria in a sample of the Canadian adult population.

Authors:  L Pelletier; P Duclos; P Gill; A Deforest
Journal:  Can J Infect Dis       Date:  1998-11

2.  Determination of diphtheria toxin neutralizing antibody titers with a cell protein synthesis inhibition assay.

Authors:  E Padovan; E Papini; R Rappuoli; C Montecucco
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

3.  Serological survey on the immunity to diphtheria of the northern Greek population.

Authors:  E Souliou; V Kyriazopoulou; E Diza; M Hatzistylianou; F Frantzidou
Journal:  Eur J Epidemiol       Date:  1997-07       Impact factor: 8.082

4.  Immune status against diphtheria among immigrants from the former USSR who arrived in Israel during 1990-1991.

Authors:  M Low; R Almog; M S Green; S Ashkenazi; H Bercovier; E Katzenelson; I Ashkenazi; J Shemer; D Cohen
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

5.  Immunity to diphtheria in northern Norway and northwestern Russia.

Authors:  P A Jenum; V Skogen; E Danilova; A Eskild; H Sjursen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-09       Impact factor: 3.267

6.  Human antibody response to fragments A and B of diphtheria toxin and a synthetic peptide of amino acid residues 141-157 of fragment A.

Authors:  V Y Perera; M J Corbel
Journal:  Epidemiol Infect       Date:  1990-12       Impact factor: 2.451

7.  Immunity against diphtheria in adults in Poland.

Authors:  A Galazka; B Kardymowicz
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

8.  Diphtheria antitoxin levels in the Netherlands: a population-based study.

Authors:  H E de Melker; G A Berbers; N J Nagelkerke; M A Conyn-van Spaendonck
Journal:  Emerg Infect Dis       Date:  1999 Sep-Oct       Impact factor: 6.883

9.  Evaluation of antidiphtheria toxin nanobodies.

Authors:  Ghada H Shaker
Journal:  Nanotechnol Sci Appl       Date:  2010-06-17

10.  No influence of atopic diseases on antibody titres following tetanus, diphtheria and hepatitis B immunisation among adults.

Authors:  N Friedrich; A Kramer; R Mentel; L Gürtler; U John; H Völzke
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.